Your browser doesn't support javascript.
COVID-19 hospitalisations and all-cause mortality by risk group in Finland.
Summanen, Milla; Kosunen, Mikko; Kainu, Ville; Cansel, Anniina; Niskanen, Severi; Nurmi, Lalli; Leskelä, Riikka-Leena; Isomeri, Outi.
  • Summanen M; Pfizer Biopharma Group, Pfizer Oy, Helsinki, Finland.
  • Kosunen M; Pfizer Biopharma Group, Pfizer Oy, Helsinki, Finland.
  • Kainu V; Pfizer Biopharma Group, Pfizer Oy, Helsinki, Finland.
  • Cansel A; NHG Finland, Nordic Healthcare Group, Helsinki, Finland.
  • Niskanen S; NHG Finland, Nordic Healthcare Group, Helsinki, Finland.
  • Nurmi L; NHG Finland, Nordic Healthcare Group, Helsinki, Finland.
  • Leskelä RL; NHG Finland, Nordic Healthcare Group, Helsinki, Finland.
  • Isomeri O; NHG Finland, Nordic Healthcare Group, Helsinki, Finland.
PLoS One ; 18(5): e0286142, 2023.
Article in English | MEDLINE | ID: covidwho-2326514
ABSTRACT
Ever since COVID-19 was announced as a global pandemic in March 2020, healthcare systems around the world have struggled with the burden of the disease. Vaccinations and other preventive measures have decreased this burden, but severe forms of COVID-19 leading to hospitalizations and even deaths still effect certain risk groups, such as the elderly and patients with multiple comorbidities. The objective of this retrospective observational study was to identify which risk groups are at the highest risk for a severe COVID-19 infection in Finland using national registry data ranging from January 2021 to June 2022. The data was analysed in three time periods, enabling comparisons in high-risk groups between epidemiological waves caused by different variants of SARS-CoV-2. The summary level data were stratified according to predefined groups based on two criteria age (≥18 years, 18-59 years, and ≥60 years) and risk group. The results include analysis of infection hospitalisation rate (IHR), case fatality rate (CFR) and average length of stay (LOS) in both primary and specialty care for each risk group and age group. Our results confirm that despite the decrease in COVID-19 hospitalisations and deaths observed during the study period, a significant proportion of patients are still hospitalised, and deaths occur especially in the 60+ population. Also, even though the average length of stay of hospitalised COVID-19 patients has decreased, it is still long compared to specialty care hospitalisations in general. Old age is a significant risk factor for severe COVID-19 in all patient groups and certain risk factors such as chronic kidney disease clearly increase the risk for severe COVID-19 outcomes. Early treatment should be considered with a low threshold for risk group patients and for elderly patients in order to avoid severe disease courses, and to ease the burden on hospitals where resources are currently very strained.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adolescent / Aged / Humans Country/Region as subject: Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Journal.pone.0286142

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adolescent / Aged / Humans Country/Region as subject: Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Journal.pone.0286142